美柏资本（MyBioCapital）：2021年中国医药行业BD交易报告（英文版）（27页）.pdf

1、2021 Annual BD Deals Report for China Pharmaceutical Industry MyBioCapitalDeclarations&Data Source Data source:data and info officially disclosed to publicData analysis:the data may be not complete,the analysis only based on the available statisticsFor purpose of reference only.For commercial purpos

2、e is not allowedThis report does not constitute any investment advice目录目录CONTENTS Cross-boarder BD Deals OverviewCross-boarder License-in Deals -Increasing trend of cross-boarder License-in deals -Top 10 cross-boarder License-in deals -Change on clinical phases for recent 10 years License-in deals -

3、Change on therapeutic fields for recent 10 years License-in deals -Therapeutic categories overview on 2021 cross-boarder License-in deals -Dealers Analysis on 2021 Cross-boarder License-in DealsCross-boarder License-out Deals -Increasing trend of cross-boarder License-out deals -Top 10 cross-boarder

4、 License-out deals -Change on clinical phases for recent 10 years License-out deals -Change on therapeutic fields for recent 10 years License-out deals -Dealers Analysis on 2021 Cross-boarder License-in DealsDeals Between Chinese BiosSummaryBased on PharmaGo database statistics，83 new drugs have bee

5、n approved by NMPA in 2021，among which 51 from China and 32 from overseas.From therapeutic category aspects,38 chemical drugs,33 biologicals(including antibodies,recombinant proteins,ADCs,vaccines,cell therapies,allergenic products,etc.),12 Traditional Chinese Medicines have been approved in 2021.Ac

6、cording to Informa latest statistics,60 new drugs have been approved by FDA in 2021,with approval no.ranged from 57 to 66 in recent 5 years.Look back to the 10 years data,2021 has been among one of the top 3 numbers.39274145224659485350681012611675100183553702012201320142015201620172018201920202021F